Pharmaceutical research has been undergoing a transformation. The tightening regulations and the shift in market requirements are driving considerable changes in the way new drugs are being developed and produced. Seeing this shift happening, we have focused on this market in this special issue. The cover story of this issue features Cogent Life Science which is mainly into developing key starting material and the advanced intermediates. The company uses flow reactors to manufacture the molecules while bringing down the cost of production. It also actively leverages Artificial Intelligence to develop a holistic and data-driven model, thereby paving the way for intelligent manufacturing. It is an ISO 9001 certified cGMP approved company, and its state-of-the-art infrastructure can handle complex and challenging chemistries in safe environments. Also featuring in the issue is Actis Pharma which is involved at the lower end of the value chain, and this sets it apart. Its team identifies and prepares intermediates that are in the phase II or phase III clinical trials. Hence, once the innovator receives approval from the FDA, it is also ready with a broad technology for the synthesis. It is witnessing 25 to 30 percent growth on a year over year basis. Currently, it has more than 70 clients that comprise top Indian, European and Japanese pharma entities. Reading on you will find more such stories.

Keeping tabs on this market, we have shortlisted the top 10 companies that have exhibited an unrelenting pursuit for excellence. By proving their dedication to fulfilling customer expectations and contributing to the market’s evolution through their innovative disposition, these companies are blazing a trail for others to follow and setting an example for them.

We look forward to receiving your feedback and suggestions.